A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

← catalyst calendar

NCT07554521 · readout in 1,959 d

Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

30estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-04-30

actual

When the study began enrolling

Primary completion

2031-12-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2031-12-31

estimated

The whole study's end, after follow-up

First posted

2026-04-28

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Advanced Unresectable Gastric Adenocarcinoma
Esophageal Squamous Cell Carcinoma
Advanced Gastroesophageal Adenocarcinoma

Interventions

Drug: Tislelizumab — also filed as BGB-A317
Drug: Capecitabine
Drug: 5-fluorouracil (5-FU)
Drug: Oxaliplatin
Drug: Leucovorin

Primary outcome

what the primary-completion date above is the date OF

Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

measured Approximately 12 months

Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed